|Bid||184.55 x 800|
|Ask||186.50 x 800|
|Day's Range||184.83 - 186.99|
|52 Week Range||163.31 - 201.23|
|PE Ratio (TTM)||60.67|
|Forward Dividend & Yield||5.28 (2.85%)|
|1y Target Est||N/A|
Data Presented at the 78th Scientific Sessions of the American Diabetes Association THOUSAND OAKS, Calif. , June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repatha ...
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif. , June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that ...
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avangrid, ...
THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomib).
In the news release, Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference, issued 07-Jun-2018 by Amgen over PR Newswire, we are advised by the company that the 1st paragraph, ...
"We are pleased that today's EC approval provides physicians with a new treatment option for bone loss associated with the use of glucocorticoid medications," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Long-term glucocorticoid therapy is associated with a rapid and early decline in bone mineral density and increase in fracture risk," said Professor Dr. Willem F. Lems, researcher and rheumatologist, VU University Medical Centre, Amsterdam.
THOUSAND OAKS, Calif. , June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday , June 12, 2018, in Rancho ...
Amgen's First Public-Private Partnership with a State Medicaid Agency to Help Improve Patient Health Care Needs Through Data, Science and Information THOUSAND OAKS, Calif. and OKLAHOMA CITY , June 6, 2018 ...
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen Prespecified Interim Analysis Presented Today ...
THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies nearing clinical development or those that have already begun the process with MD Anderson's translational medicine capabilities.
In a study published today, scientists at deCODE genetics report new findings about the founding of the Icelandic population and its subsequent evolution, based on ancient DNA. Iceland was settled around 1100 years ago, at the height of the Viking age. By sequencing the genomes from 25 ancient skulls dating to the first generations of settlement, and comparing them to genomes from the contemporary inhabitants of Iceland, Scandinavia and the British and Irish Isles, the deCODE team was able to demonstrate that most of the settlers were of unmixed Norse or Gaelic ancestry.
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., May 30, 2018 /PRNewswire/ -- The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process. "There are many millions of students who, as a result of economic or geographic limitations, simply do not have access to one of the most central aspects of being a scientist, which is working in a laboratory," said Professor Robert Lue, principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard.
THOUSAND OAKS, Calif., May 23, 2018 /PRNewswire/ -- Amgen (AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes. The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks through Connected Health) program will use human-centered design methodologies to identify the needs of patients, caregivers and healthcare providers.
THOUSAND OAKS, Calif., May 22, 2018 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 90 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors.
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data from a Phase 3 study which showed patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density (BMD) compared to those who received active comparator (risedronate).
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / A selloff in technology stocks and elevated bond yields combined to pressure U.S. equities lower on Thursday. The Dow Jones Industrial Average dropped 0.22 percent ...
THOUSAND OAKS, Calif., May 17, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R) – which is believed to play a critical role in migraine.
THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the expanded label now in place, Amgen is working with payers in Europe to remove prescribing barriers and expand access in order to reach patients with established cardiovascular disease who are at risk of another event.
THOUSAND OAKS, Calif. , May 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018 . David W. ...
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif. , April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) ...
THOUSAND OAKS, Calif., April 27, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. "Today's positive opinion by the CHMP is an important step for Prolia in helping patients suffering from bone loss associated with systemic glucocorticoid therapy," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Zai Lab Ltd (NASDAQ: ZLAB). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZLAB as the Company's latest news hit the wire. On April 25, 2018, the Company announced that it has inked an exclusive license agreement with Entasis Therapeutics Holdings Inc. ("Entasis") for the rights to ETX2514, which is a novel broad-spectrum intravenous inhibitor of β-lactamases, in the Asia/Pacific region.
LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on argenx SE (NASDAQ: ARGX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARGX as the Company's latest news hit the wire. On April 24, 2018, the Company announced that it will present complete data from the Phase-2 proof-of-concept trial assessing efgartigimod (ARGX-113) in generalized myasthenia gravis (MG) patients at the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, California.
PRESS RELEASE: REGULATED INFORMATION Thursday, 26 April 2018, 07:00 CEST BIOCARTIS Q1 2018 BUSINESS UPDATE Mechelen, Belgium , 26 April 2018 - Biocartis Group NV (the `Company` or `Biocartis`), an ...